All Industries

New Era Helium Begins Trading on the Nasdaq Under Symbol “NEHC"

New Era Helium Inc

New Era Helium, Inc. (“NEH,” “New Era Helium” or the “Company”), an exploration and production company sourcing helium produced in association with the production of natural gas reserves within the Permian Basin, is pleased to announce it has closed on its previously announced business combination with Roth CH V Holdings, Inc. (“Holdings”), and Roth CH Acquisition V. Co. (Nasdaq: ROCL; ROCLU and ROCLW) (the “Business Combination”), in which NEH merged with Roth CH V Merger Sub Corp., a wholly-owned subsidiary of Holdings. The transaction was approved by ROCL’s stockholders on November 26, 2024. With the transaction now complete, Holdings has changed its name to “New Era Helium, Inc.”. The combined company will operate under the new name, “New Era Helium, Inc.” and is set to begin trading on Nasdaq under the ticker symbols “NEHC” and “NEHCW” on December 9, 2024. On December 6, 2024, NEH, Roth CH Acquisition V. Co., and ATW Partners Opportunities Management, LLC (“ATW”) entered into a series of financing transactions including an equity purchase agreement for $75 million, an advance of $10 million in senior secured notes of which $7 million was advanced at closing and up to an additional $3 million will be advanced subject to the satisfaction of certain conditions, and the issuance of warrants to purchase up to an additional $30 million in common stock. The trading of the Company’s shares on Nasdaq represents a pivotal milestone in New Era Helium’s mission to establish itself as a leading consolidator of helium and natural gas production. With over 137,000 acres in Southeast New Mexico and 1.5 billion cubic feet of proved and probable helium reserves, NEH is well-positioned to drive growth in this critical sector, expected to see a surge in demand amid growth in data centers powering artificial intelligence. Last month [read here], NEH announced a non-binding joint venture with Sharon AI, Inc. (“Sharon AI”) to build a 90MW net-zero Tier 3 data center to be located within the Permian Basin. This joint venture combines Sharon AI’s expertise in high-performance computing with NEH’s extensive helium and natural gas reserves. The state-of-the-art facility will feature a liquid-cooled Tier 3 data center powered by sustainable energy, offsetting approximately 250,000 metric tons of CO 2 annually through carbon capture technology. NEH believes the Nasdaq listing will enhance its visibility and attract U.S. investors interested in energy infrastructure and sustainable innovation, further underscoring the value of its assets and forward-looking projects. E. Will Gray II, Chairman and Chief Executive Officer of New Era Helium, said: “Our Nasdaq listing marks a significant moment in our corporate journey, enhancing our public profile within the industry, and broadening our reach to institutional investors in the AI datacenter, and Helium markets.Thank you to all of our shareholders and partners whose unwavering support has been instrumental in driving our ongoing success.” About New Era Helium, Inc. New Era Helium, Inc. is an exploration and production company that sources helium produced in association with the production of natural gas reserves in North America. The Company currently owns and operates over 137,000 acres in Southeast New Mexico and has over 1.5 billion cubic feet of proved and probable helium reserves. For more information, visit www.newerahelium.com. Follow New Era Helium on LinkedIn and X. Forward Looking Statements‍ This press release contains forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any expected future results, performance, or achievements. Forward-looking statements are typically identified by words or phrases, such as “about,” “believe,” “expect,” “plan,” “goal,” “target,” “strategy,” and similar expressions or future or conditional verbs such as “may,” “will,” “should,” “would,” and “could.” Forward-looking statements are based on our current estimates or expectations of future events or future results and are subject to risks and uncertainties and actual results could differ materially from those indicated by these statements. including risks relating to our industry, business operations, financing and liquidity, regulation and other risks described in the registration statement. A discussion of these and other factors with respect to the Company is set forth in the Company’s reports filed with the Securities and Exchange Commission. The forward-looking statements included in this press release are made and based on information available at the time of the press release, and the Company assumes no obligation to revise or update any forward-looking statement as a result of new information, future events or otherwise. Contact Details CEO E. Will Gray II Will@NewEraHelium.com Investor Relations Jonathan Paterson +1 475-477-9401 Jonathan.Paterson@harbor-Access.com Company Website http://www.newerahelium.com

December 09, 2024 11:55 AM Eastern Standard Time

PathAI Launches AIM-IHC Breast Panel on AISight® Platform to Streamline Breast Cancer Biomarker Quantification and Improve Pathologist Efficiency

PathAI

PathAI, a leader in AI-powered pathology solutions, today announced the launch of the AIM-IHC Breast Panel, a set pf advanced AI-assisted, algorithms designed to quantify critical breast cancer biomarkers—HER2, ER, PR, and Ki-67. Available now on the AISight® Image Management System (IMS), this comprehensive panel provides partners with accurate, consistent scoring, enhancing precision and streamlining workflow efficiency. Adding to the existing AIM-HER2 Breast solution, this consolidation of critical breast cancer biomarker algorithms into a single, pathologist-centric image management system directly addresses the need for standardized, reliable quantification assist tools to support pathologists. PathAI’s AIM-IHC Breast Panel is designed to address key challenges in breast cancer biomarker quantification, particularly the need for precise and reproducible assessment. The panel provides accurate, consistent, zero-click scoring for HER2, ER, PR, and Ki-67 directly from routine immunohistochemistry (IHC) images. With automated tissue segmentation and detection of on-slide controls, the panel classifies areas of invasive versus non-invasive cancer and provides overlays to support algorithmic scoring. This breast cancer-centric panel is designed for a pathologist-assist workflow, allowing users to better differentiate regions of interest, improve the accuracy of invasive cancer segmentation, and streamline tedious scoring processes. The AIM-IHC Breast Panel is the latest addition to PathAI's expanding suite of AI-powered solutions on the AISight® IMS. AISight serves as a central hub for managing pathology images, enabling seamless integration of various AI-driven tools for pathology labs. By centralizing workflows and offering a growing portfolio of applications, PathAI empowers pathologists and researchers to improve precision and efficiency, all within a unified, cloud-native platform. This continuous expansion of the AISight IMS and the full menu of AI applications available on the platform from PathAI as well as third-party vendors underscores PathAI’s commitment to providing comprehensive, reliable tools that enhance the field of pathology and ultimately, patient outcomes. “We are committed to advancing precision pathology with cutting-edge AI technology, empowering pathologists with the tools to make more accurate, consistent, and efficient assessments,” said Andrew Beck, CEO of PathAI. “The AIM-IHC Breast Panel is the latest step in our mission to enhance AI-powered scoring for key breast cancer biomarkers.” In addition, the AIM-IHC Breast Panel goes beyond HER2 by offering fast and accurate Ki-67 scoring, addressing the challenges of this emerging biomarker, which has traditionally been time-consuming and labor-intensive. Pathologists no longer need to spend significant time manually counting cells or rely on imprecise approximations. The panel’s automated features, such as classifying invasive cancer and generating percentage-based results for positive cancer cells, provide pathologists with the clarity needed to produce more accurate scoring. The introduction of the AIM-IHC Breast Panel marks a significant step in PathAI’s ongoing mission to enable precision pathology and empower pathologists with the latest AI-driven technologies. This release highlights PathAI’s commitment to improving workflow efficiency, speed, and assessment accuracy. As the AISight® Image Management System continues to expand with new solutions, pathologists gain access to a comprehensive suite of tools that streamline their workflow, accelerating decision-making and reducing time spent on manual tasks. With each of our new advancements, pathologists are better equipped to deliver precise, actionable insights for cancer diagnostic research. Footnotes AIM-IHC Breast Panel, AIM-HER2, AIM-ER, AIM-PR, and AIM-Ki-67 are for research use only. Not for use in diagnostic procedures. AISight is for Research Use Only in the US; AISight Dx is CE-IVD marked in Europe, UK and Switzerland. About PathAI PathAI is a global leader in AI-powered digital pathology solutions, dedicated to improving operational efficiency in pathology labs worldwide. Through its innovative technology and strategic partnerships, PathAI is shaping the future of medical diagnostics and advancing patient care across the globe. Contact Details SVM Public Relations and Marketing Communications +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

December 09, 2024 10:00 AM Eastern Standard Time

UNOS and Donate Life America invite you to honor donors

United Network for Organ Sharing

The United Network for Organ Sharing (UNOS) and Donate Life America (DLA) invite the public to join the National Tree of Life virtual event to honor and remember this year’s organ, eye and tissue donors and their families. The National Tree of Life ceremony will take place on December 16 at 6:30 p.m. ET. The annual event honors the legacy of donors in each state who gave the gift of life in 2024 and celebrates the tens of thousands of lives they saved. The event will be live streamed on Donate Life America’s Facebook page. As part of this year’s ceremony, the winner of the annual Lisa Schaffner Community Advocate Award will be announced. The award recognizes those who go above and beyond to promote organ donation. The award is named after Lisa Schaffner, a powerful advocate of donation and transplant and former UNOS employee, who passed away in 2021. The ceremony will feature speakers from DLA, UNOS and the organ donation and transplant community, including: Jan Flanders, a tissue recipient and family member of an organ donor Sam Dey, a heart recipient Samuel and Susan Kirton, a double lung recipient and a caregiver Each year, the Tree of Life ceremony recognizes the lives and gifts of more than 20,000 organ donors – and tens of thousands of cornea and tissue donors – and their families, while also celebrating the lives of recipients across the country. Volunteers with connections to donation and transplant will honor donors from each state by hanging ornaments on the trees of life and lighting candles of remembrance. “The Tree of Life event is a moving reminder of the tremendous loss, bravery and joy that organ donation and transplant bring, and the ripple effect it has on each of us,” said Maureen McBride, Ph.D., CEO of UNOS. “We are thankful for those who have given the gift of life and for their courageous families.” “As we honor donors and donor families from this year during the National Tree of Life ceremony, we also recognize and celebrate the enduring legacy of lifesaving generosity of all donors and donor families who have given the gift of life in past years,” said David Fleming, DLA president and CEO. “We hope the Tree of Life ceremony helps provide community and solace.” Watch the event on the National Tree of Life Facebook event page: https://www.facebook.com/share/18T7djHSUJ/. For more information about organ, eye and tissue donation and how to register to be a donor, visit donatelife.net. About UNOS The United Network for Organ Sharing (UNOS) is a nonprofit organization that serves the organ donation and transplant system and broader public health community through its work developing new technologies and initiatives, conducting data-driven research and analysis, providing expert consulting services, advocating for patients, and being a leader in bringing communities together to save lives. About Donate Life America Donate Life America (DLA) is a 501(c)3 nonprofit organization leading its national partners and Donate Life State Teams to increase the number of donated organs, eyes and tissues available to save and heal lives. DLA owns, manages and promotes Donate Life℠, the national logo and brand for the cause of donation; motivates the public to register as organ, eye and tissue donors; provides education about living donation; owns and manages the National Donate Life Registry at RegisterMe.org and develops and executes effective multi-media campaigns to promote donation. Contact Details United Network for Organ Sharing Anne Paschke anne.paschke@unos.org Donate Life America Hilary Kleine media@donatelife.net Company Website https://unos.org

December 09, 2024 09:40 AM Eastern Standard Time

Image

For the Second Year in a Row, Shareholder Calls for Microsoft Shareholders to Reject Reid Hoffman

NLPC

The annual meeting for Microsoft Corporation is on Tuesday, and for the second year in a row, an investor is calling upon shareholders to oppose the re-election of tech entrepreneur and political agitator Reid Hoffman to the board of directors. Earlier this year, National Legal and Policy Center sent a letter to Microsoft Corporation calling upon Hoffman to resign from the board, and if he refused, then for his fellow directors to call a special meeting to vote on his removal. The shareholder group wrote that he should not continue to serve on Microsoft’s board, after Hoffman wished for the death of former President Donald Trump just days before an attempted assassination on the now President-elect. The letter, sent in July, followed NLPC’s plea last year in advance of the tech company’s 2023 annual meeting, which asked voting shareholders to oppose Hoffman’s re-election to a seat on the board. NLPC argued then (and argues now) that the former member of the “Paypal mafia” harbors an unhealthy obsession with the personal and political destruction of President-elect Trump, and that he displays an intolerance and temperament that is unbefitting for a director of a prestigious multinational corporation like Microsoft. NLPC also called into question Hoffman’s extremely poor judgment in his visit to Little Saint James island with multi-millionaire financier and sex offender Jeffrey Epstein, as well as his regular associations with him, many years after the pedophile was convicted for the abuse of underage girls. For these same reasons, NLPC demanded that Hoffman be removed as a member of the Defense Department’s Innovation Advisory Board “Under any other circumstances, Reid Hoffman’s caustic rhetoric, his reckless conduct, and his preoccupation with the destruction of a political foe, would disqualify him from the privilege of serving on a corporate board,” said Paul Chesser, director of the Corporate Integrity Project for NLPC. “Corporate America seems to be coming to their senses finally on issues like DEI and the transgender delusion, so maybe shareholders will finally reject an extremist like Mr. Hoffman, because they should.” NLPC released a satirical video in October that identified several of Hoffman’s sins and shortcomings that make him unqualified for Microsoft’s board of directors. ### For more information or to schedule an interview with Paul Chesser, contact Dan Rene at 202-329-8357 or drene@nlpc.org. Please visit http://www.nlpc.org. Founded in 1991, the National Legal and Policy Center promotes ethics in public life through research, investigation, education and legal action. Contact Details National Legal and Policy Center Dan Rene +1 202-329-8357 drene@nlpc.org Company Website http://www.nlpc.org

December 09, 2024 09:00 AM Eastern Standard Time

Bolt Metals Corp. (CSE: BOLT) Makes A Power Move: Strategic Acquisition Of Copper-Silver Assets Signals Expansion

Benzinga

By Gerelyn Terzo, Benzinga Commodities prices are hovering at their highest levels since April, owing to a perfect storm of geopolitical tensions and high demand. The gold price, in particular, has grabbed the spotlight, with market predictions targeting the $3,000/ounce level as investors seek portfolio diversification and a hedge against inflation. Not to be outdone, copper – one of the first metals used by humans – has been on the rise, too, amid a softening U.S. dollar that makes the price of the precious metal more attractive to international investors. Silver remains volatile but has struggled to break out of the $30/ounce area of late. One company that could be strategically positioned to benefit from these market dynamics is Bolt Metals (CSE: BOLT, OTCMKTS: PCRCF), a mineral exploration company with projects in gold, copper and silver underway. With over two decades of operating history behind it, Vancouver, B.C.-based Bolt Metals is no stranger to North American metals exploration. Led by a seasoned management team with mining and leadership experience, including CEO Branden Haynes, the company is pursuing expansion to capitalize on an evolving industry landscape that favors metals miners. Bolt Metals is preparing for greater drilling activity in the new year, and has said it will accelerate exploration initiatives in Montana, focusing on its 100% controlled, Soap Gulch property. The company feels the move is aligned with the incoming US government, which values domestic resource independence and economic growth. “The Trump administration’s focus on unleashing American energy and resource industries has created a pathway for exploration companies to play a pivotal role in securing the nation’s economic future. We are proud to align with this vision by prioritizing domestic exploration efforts that can lead to job creation, innovation and enhanced national security,” Haynes stated. If you’d like to see what all the excitement is all about, you can learn more about Bolt Metals’ mining assets here. Bolt Metals Growing Through Acquisition After announcing the strategic acquisition of what’s dubbed the Switchback Copper-Silver property, situated in British Columbia’s Omineca Mining Division, Bolt Metals has brought this deal full circle. In recent weeks, Bolt Metals has closed that transaction with 143 B.C., the previous owner of a beneficial interest in the assets. The cash and stock deal included the issuance of 4 million common shares to 143 B.C. investors coupled with a cash payment of $20,000 to the seller. The addition of this exploration-stage property could be a score for Bolt Metals, not least for its close proximity to Terrace, B.C. The property comprises eight contiguous mineral claims across 2,560 hectares (6,324 acres), boasting potential for highly coveted volcanic redbed copper, which is famous for its “scientific intrigue and economic significance,” as well as polymetallic copper-silver-lead zinc deposits. These deposits represent a geological formation comprising notable amounts of a combination of copper, silver, lead and zinc. The deal comes at a time when M&A activity has been on the rise in the metals and mining industry, as evidenced by a 15% year-over-year increase in deal volume in Q2 2024 across 358 transactions. Over the past decades, mining industry consolidation has been steady, owing to market dynamics, technological innovation, industry growth challenges and economic conditions. Last year, the metals and mining sector experienced nearly 2,700 deals with an overall value of $228 billion. State Of The Newly Acquired Copper-Silver Assets Now that Bolt Metals owns 100% of the Switchback Copper-Silver Property, it has published a technical report on the state of the assets. The company proactively issued the report to present a baseline overview of the property ahead of a further expansion planned for 2025 on the heels of a phase 1 exploratory program. Prepared by geoscientist Jeremy Hanson, the report advises the further exploration of the Switchback Copper-Silver Property, suggesting a trenching program to test the degree of surface mineralization within the structure. In doing so, the company hopes to gain a clear understanding of the property’s mineralization potential while also gaining necessary insights for upcoming drilling programs. So far, exploration on this property has involved mapping, sampling and drilling leading to results that consistently produce “significant anomalous areas and prospective targets,” noted in the announcement. If Bolt Metals has piqued your interest and you are looking for a way to diversify your portfolio with precious metals including gold, silver and copper, you can dive into the company’s capital structure here. Featured photo by sakulich on Pixabay Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

December 09, 2024 08:45 AM Eastern Standard Time

Image

Teambuilder Receives Patent for Predictive Staff Scheduling in Healthcare

TeamBuilder

TeamBuilder has been granted Patent No. 12148523 for its predictive staff scheduling technology. The patent covers TeamBuilder’s innovative approach of weaving patient volume, workflow and employee availability and characteristics into an easy-to-use interface that managers can use to make optimal scheduling decisions. This achievement underscores TeamBuilder’s commitment to leveraging data-driven solutions to improve staffing efficiency, reduce costs, and enhance patient care. “Securing a patent for our predictive staff scheduling technology is a significant milestone for TeamBuilder, confirming the innovation behind our solution,” said David Howard, Founder and CEO of TeamBuilder. “Our technology addresses the complex staffing challenges healthcare providers face today, offering a smarter, more efficient way to manage workforce needs while improving both staff and patient outcomes.” Staff scheduling in healthcare is inherently complex, with fluctuating patient demand, varying specialty needs, multiple locations, and diverse staff preferences. Despite this, many healthcare organizations continue to rely on staffing ratios and manual scheduling systems, such as paper or Excel-based methods, which often lead to overstaffing, administrative inefficiencies, and a lack of visibility into key operational metrics. How TeamBuilder Works: Schedule Optimization: Develops the most efficient schedule by balancing patient demand, staff availability, workload, and clinic constraints, minimizing gaps in coverage. Staff Allocation: Focuses on analyzing staff availability and workload to predict the optimal number of staff needed for each shift, ensuring the right coverage in alignment with patient demand. Operational Visibility: Provides real-time insights into clinic operations, resource allocation, and clinic-to-clinic comparisons, enabling data-driven staffing adjustments and resource planning. Performance Tracking: Tracks key metrics such as resource cost per visit and peer benchmarking to evaluate and enhance operational efficiency. “The shift toward data-driven predictive scheduling is no longer optional—it’s essential,” says Niel Oscarson, Research Director at KLAS. “Healthcare organizations that can accurately forecast staffing needs will see improvements in both operational efficiency and patient care quality. Our conversations with TeamBuilder customers indicate that Teambuilder is making a significant impact with its patented technology, creating new and significant efficiencies in workforce management. Additionally, TeamBuilder’s focus on the ambulatory care space addresses a critical area of need.” TeamBuilder’s patented staff scheduling technology not only transforms workforce management but also drives tangible, measurable improvements. Healthcare organizations have seen an 11% improvement in access to care and payroll reductions of 9-14% through optimized staffing. The technology also enhances communication and reduces the time required to create and manage schedules, streamlining operations. These outcomes highlight TeamBuilder’s impact on improving efficiency, reducing costs, and enhancing patient care. About TeamBuilder: TeamBuilder is an innovator in healthcare workforce management, offering a smart scheduling solution powered by patented predictive technology. By combining data science with intuitive scheduling interface, TeamBuilder helps healthcare organizations optimize staffing, reduce costs, and improve patient care. The platform’s focus on predictive scheduling is reshaping how healthcare facilities approach workforce management, ultimately benefiting both staff and patients. For more information about TeamBuilder, visit www.teambuilder.io or contact Mea Parikh About KLAS Research: KLAS Research is a leading healthcare research firm that provides insights into healthcare technology solutions. Their reports help organizations make informed decisions by offering accurate, independent evaluations of products and services. Contact Details Mea Parikh Marketing and Business Development mea@teambuilder.io Company Website https://teambuilder.io/

December 09, 2024 08:30 AM Eastern Standard Time

The Uber Of Advertising? This Company Is Helping Democratize The Industry

Benzinga

By Johnny Rice, Benzinga Robert Steele, CEO of Thumzup Media Corporation (NASDAQ: TZUP), was recently a guest on Benzinga’s All-Access. Thumzup offers people the ability to get paid to post about their favorite products on social media. By connecting brands to consumers through trusted friends, Thumzup has created a way to bypass the traditional model, allowing anyone to earn. Mr. Steele spoke about his “flywheel” approach to marketing the platform. After a successful launch in Los Angeles, the company is launching in Miami. Watch the interview here: Featured photo by NordWood Themes on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

December 09, 2024 08:30 AM Eastern Standard Time

Video Image

OYO Bucks Industry Trend in the US with 16% Jump in Online Summer Booking Revenue

OYO

Travel-tech platform sees 15% increase in online bookings compared to last year Midwest and Northeast emerge as standout performers with 44% and 46% growth, respectively OYO is expanding its US presence through the acquisition of Motel 6 and Studio 6 brands Global hospitality technology company OYO reported a 16% increase in summer booking revenue (June to August) in the US compared to last year, according to STR, significantly outperforming the broader economy hotel segment that experienced a 2% decline, underlining its growing footprint in the world’s largest hotel market. The growth was primarily driven by a 15% increase in bookings across OYO hotels in the US. The company saw particularly robust performance in the Midwest and Northeast regions, recording 46% and 44% growth in booking revenue respectively, substantially outpacing the market growth of 22% and 24%. Nikhil Heda, Head of Business Development – OYO US said, “Our strong performance this summer demonstrates the growing preference for OYO's value proposition in the US market. By focusing on delivering quality accommodations at competitive prices, backed by our technology platform and online demand generation expertise, we’ve been able to capture increasing demand despite broader market headwinds.” Texas emerged as the top-performing state, contributing 22% of OYO's overall summer booking revenue, followed by Oregon (18%), Florida (7%), and Louisiana (6%). At the city level, Newport, Oregon, and Houston, Texas each contributed 5% to the overall summer booking revenue, while Seaside accounted for 4%. In an encouraging trend, destinations such as Houston, Port Allen, Rockford, Portland demonstrated exceptional growth, significantly surpassing market averages. OYO enhances the guest experience through its technology-driven platform, offering seamless bookings, dynamic market-based pricing, AI-powered customer support, and flexible cancellation policies. The platform's integrated loyalty program further rewards customers while ensuring competitive rates. The India-headquartered company’s impressive performance augurs well for its growth prospects in the US as it closes in on concluding its acquisition of G6 Hospitality, which owns the iconic Motel 6 and Studio 6 brands. Oravel Stays, the parent company of OYO, inked a deal with Blackstone Real Estate to buy G6 Hospitality, which has a franchise network of around 1,500 hotels across the US and Canada. OYO has steadily expanded its footprint in the US since its launch in the region in 2019 and currently operates over 400 hotels across 35 states. In 2023, OYO added nearly 100 hotels to its US portfolio and aims to add ~250 hotels in 2024. OYO will leverage its comprehensive technology suite as well as its global distribution network and marketing expertise to further strengthen the Motel 6 and Studio 6 brands and drive continued financial growth. About OYO OYO is a global platform that empowers entrepreneurs and small businesses with hotels and homes by providing full-stack technology products and services that aim to increase revenue and ease operations; bringing easy-to-book, affordable, and trusted accommodation to customers around the world. OYO offers 40+ integrated products and solutions to patrons who operate over 184K hotel and home storefronts in more than 35 countries including India, Europe and Southeast Asia. For more information, visit here. Contact Details OYO Anupriya Malik +91 97911 63065 anupriya.d@oyorooms.com Company Website https://www.oyorooms.com/

December 09, 2024 08:00 AM Eastern Standard Time

Supreme Court Of New York Awards RedHill Biopharma Approx. $8 Million Plus Costs In Breach Of Contract Lawsuit

Benzinga

By Meg Flippin, Benzinga RedHill Biopharma Ltd. (NASDAQ: RDHL), a specialty biopharmaceutical company, won a significant legal and financial victory, announcing a summary judgment in its favor and an award of about $8 million plus costs in its New York Supreme Court case against Kukbo Co. Ltd. o f South Korea. RedHill Biopharma sued Kukbo over a breach of contract related to opaganib, the company’s first-in-class orally administered sphingosine kinase-2 (SPHK2) selective inhibitor with anticancer, anti-inflammatory and antiviral activity, targeting multiple indications. Opaganib has several U.S. government and academic collaborations in place for development for radiation and chemical exposure indications such as Acute Radiation Syndrome (ARS), a phase 2/3 program for hospitalized COVID-19, and a phase 2 program in oncology. Breach Of Contract At The Heart Of Lawsuit The lawsuit stemmed from Kukbo’s failure to make agreed payments to RedHill pursuant to a subscription agreement signed on Oct. 25, 2021, and a subsequent exclusive license agreement inked on March 14, 2022. The two were working to develop opaganib for COVID. The Supreme Court of the State of New York ruled in favor of RedHill Biopharma and, in a summary judgment, ordered Kukbo to pay $8 million, consisting of $6.5 million plus interest amounting to approximately $1.5 million, plus costs. The court dismissed Kukbo’s counterclaims. Kukbo has a right to seek an appeal of the judgment, which may or may not be granted. RedHill intends to pursue its attorneys' fees and collection of the judgment. "RedHill thanks the Court for this crystal-clear judgment, affirming the company's just position from the beginning of the relationship and in making correct provision for full reparation for the contractual breaches,” said Dror Ben-Asher, RedHill’s CEO. Once collected, the summary judgment will give RedHill more cash to develop its pipeline and eliminates a potential overhang on the stock. TipRanks called the ruling a “significant financial victory,” one that highlights RedHill’s adherence to contractual agreements. TipRanks said the end to litigation could boost investor confidence in the company. The positive ruling comes as RedHill Biopharma is making progress in developing opaganib for infectious diseases such as Ebola. Recently, RedHill announced that the U.S. government’s Biomedical Advanced Research and Development Authority (BARDA), a center of the Department of Health and Human Services’ (HHS) Administration for Strategic Preparedness and Response (ASPR), had selected opaganib for development to treat exposure to Ebola virus disease (EBOV). Under the cost-sharing agreement with BARDA, BARDA will provide partial funding for RedHill to further advance opaganib to mitigate infections and contain EBOV outbreaks. In an in vivo EBOV study with the United States Army Medical Research Institute of Infectious Diseases, RedHill Biopharma said opaganib delivered a statistically significant increase in patient survival time when given at 150 mg/kg twice a day. RedHill Biopharma said it’s the first host-directed molecule to show activity in EBOV. Several other U.S. government countermeasures and pandemic preparedness programs have also selected opaganib for evaluation for multiple indications, reports the company. With litigation in the rearview mirror and RedHill Biopharma making progress in developing opaganib, interested investors may want to pay attention to what’s next from this specialty biopharmaceutical company. Featured photo by Scott Graham on Unsplash. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

December 09, 2024 08:00 AM Eastern Standard Time

Image

1 ... 3 4 5 6 7 ... 3786